Literature DB >> 6166877

The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374)--equipotent to PGI2 in vitro.

K Schrör, H Darius, R Matzky, R Ohlendorf.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6166877     DOI： 10.1007/BF00505658

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  22 in total

Review 1.  Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.

Authors:  S Moncada; J R Vane
Journal:  Pharmacol Rev       Date:  1978-09       Impact factor: 25.468

2.  Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia.

Authors:  A M Lefer; M L Ogletree; J B Smith; M J Silver; K C Nicolaou; W E Barnette; G P Gasic
Journal:  Science       Date:  1978-04-07       Impact factor: 47.728

3.  Prostacyclin therapy in peripheral arterial disease.

Authors:  A Szczeklik; R J Gryglewski; R Nizankowski; S Skawiński; P Głuszko; R Korbut
Journal:  Thromb Res       Date:  1980 Jul 1-15       Impact factor: 3.944

4.  The chemical structure of prostaglandin X (prostacyclin).

Authors:  N Whittaker; S Bunting; J Salmon; S Moncada; J R Vane; R A Johnson; D R Morton; J H Kinner; R R Gorman; J C McGuire; F F Sun
Journal:  Prostaglandins       Date:  1976-12

5.  dl-9a-Deoxy-9a-methylene-PGI2 (a stable prostacyclin derivative): preliminary pharmacological data.

Authors:  R Ceserani; M Grossoni; D Longiave; B Mizzotti; O Pozzi; A Dembinska-Kiec; S Bianco
Journal:  Prostaglandins Med       Date:  1980-08

6.  Metabolism of prostacyclin in rat.

Authors:  F F Sun; B M Taylor
Journal:  Biochemistry       Date:  1978-09-19       Impact factor: 3.162

7.  Contractile responses to prostacyclin (PGI2) of isolated human saphenous and rat venous tissue.

Authors:  J V Levy
Journal:  Prostaglandins       Date:  1978-07

8.  6,9-thiaprostacyclin. A stable and biologically potent analogue of prostacyclin (PGI2)

Authors:  K C Nicolaou; W E Barnette; G P Gasic; R L Magolda
Journal:  J Am Chem Soc       Date:  1977-11-09       Impact factor: 15.419

9.  Prostacyclin-induced coronary vasodilation. Interactions with adenosine, cyclic AMP and energy charge in the rat heart in vitro.

Authors:  K Schrör; H B Link; R Rösen; W Klaus; P Rösen
Journal:  Eur J Pharmacol       Date:  1980-06-27       Impact factor: 4.432

10.  Identification of the major metabolite of prostacyclin and 6-ketoprostaglandin F1 alpha in man.

Authors:  B Rosenkranz; C Fischer; I Reimann; K E Weimer; G Beck; J C FRölich
Journal:  Biochim Biophys Acta       Date:  1980-08-11
View more
  29 in total

1.  Recommendations on the management of pulmonary hypertension in clinical practice.

Authors: 
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

2.  Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury.

Authors:  Miao Wang; Kaori Ihida-Stansbury; Devashish Kothapalli; Mathieu C Tamby; Zhou Yu; Lihong Chen; Gregory Grant; Yan Cheng; John A Lawson; Richard K Assoian; Peter L Jones; Garret A Fitzgerald
Journal:  Circulation       Date:  2011-01-31       Impact factor: 29.690

3.  Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man.

Authors:  W Krause; T Krais
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Solubilization of a thromboxane A2/prostaglandin H2 antagonist binding site from human platelets.

Authors:  R M Burch; D E Mais; D L Saussy; P V Halushka
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

5.  Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers.

Authors:  W Krause; T Krais
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled dose-response study.

Authors:  H Darius; V Hossmann; K Schrör
Journal:  Klin Wochenschr       Date:  1986-06-16

7.  Prostacyclin and iloprost: equal efficiency in preserving high energy phosphates in the dog heart following coronary artery ligation.

Authors:  M Pissarek; H Goos; J Nöhring; J Graff; G Buller; I Beyerdörfer; H J Mest; K F Lindenau; E G Krause
Journal:  Basic Res Cardiol       Date:  1987 Nov-Dec       Impact factor: 17.165

8.  Clinical effects of intravenous iloprost in patients with intermittent claudication.

Authors:  U Müller-Bühl; C Diehm; T Krais; R Zimmermann; H Mörl; H H Eckstein
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.

Authors:  N J McHugh; M Csuka; H Watson; G Belcher; A Amadi; E F Ring; C M Black; P J Maddison
Journal:  Ann Rheum Dis       Date:  1988-01       Impact factor: 19.103

10.  Effects of iloprost, a PGI2 derivative, on ischemic myocardial energy and carbohydrate metabolism in dogs.

Authors:  K Ichihara; K Yamamoto; Y Abiko
Journal:  Mol Cell Biochem       Date:  1993-02-17       Impact factor: 3.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.